sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
|
lamivudine
|
adefovir dipivoxil
|
NONE
|
Entecavir_ddi.xml
|
DDI-DrugBank.d295.s1
|
DDI-DrugBank.d295.s1.p3
|
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
|
ROMAZICON
|
cyclic antidepressants
|
EFFECT
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s2
|
DDI-DrugBank.d234.s2.p0
|
The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.
|
allopurinol
|
didanosine
|
NONE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s3
|
DDI-DrugBank.d43.s3.p0
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
amiodarone
|
dofetilide
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p49
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
tranquilizers
|
anesthetics
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p64
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
Disalcid
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p5
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
phenylbutazone
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p25
|
Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
|
calcium antagonists
|
beta-adrenergic blocking agents
|
ADVISE
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s5
|
DDI-DrugBank.d489.s5.p0
|
During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
|
anticoagulants
|
antipyretics
|
NONE
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s3
|
DDI-DrugBank.d549.s3.p12
|
Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine
|
lidocaine
|
quinidine
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s57
|
DDI-DrugBank.d97.s57.p5
|
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
|
metoclopramide
|
levodopa
|
MECHANISM
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s7
|
DDI-DrugBank.d47.s7.p0
|
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
|
Barbiturates
|
anticoagulants
|
EFFECT
|
Hexobarbital_ddi.xml
|
DDI-DrugBank.d457.s0
|
DDI-DrugBank.d457.s0.p5
|
Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
|
Lithium carbonate
|
lithium carbonate
|
NONE
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s15
|
DDI-DrugBank.d158.s15.p1
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
meclofenamic acid
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p9
|
BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
|
beta2-agonists
|
monoamine oxidase inhibitors
|
ADVISE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s6
|
DDI-DrugBank.d284.s6.p4
|
It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
|
CASODEX
|
anticoagulant
|
ADVISE
|
Bicalutamide_ddi.xml
|
DDI-DrugBank.d266.s1
|
DDI-DrugBank.d266.s1.p1
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
sertraline
|
5-HT1 agonists
|
EFFECT
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p27
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
contraceptives
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p7
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
rifampin
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p8
|
The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
|
desipramine
|
alprazolam
|
MECHANISM
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s1
|
DDI-DrugBank.d131.s1.p2
|
Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
|
hormonal contraceptives
|
TRACLEER
|
EFFECT
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s8
|
DDI-DrugBank.d289.s8.p0
|
however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
|
Lodine
|
aspirin
|
ADVISE
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s6
|
DDI-DrugBank.d219.s6.p2
|
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
|
SSRIs
|
dihydroergotamine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s4
|
DDI-DrugBank.d423.s4.p6
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
hexobarbital
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p3
|
In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
|
imidazole drugs
|
coumarin drugs
|
ADVISE
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s20
|
DDI-DrugBank.d458.s20.p0
|
Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
|
nitazoxanide
|
warfarin
|
MECHANISM
|
Nitazoxanide_ddi.xml
|
DDI-DrugBank.d354.s1
|
DDI-DrugBank.d354.s1.p0
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Type 1C antiarrhythmics
|
flecainide
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p53
|
It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
|
cisapride
|
anticoagulant
|
ADVISE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s5
|
DDI-DrugBank.d237.s5.p0
|
The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
|
NSAIDs
|
ACE inhibitors
|
EFFECT
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s0
|
DDI-DrugBank.d85.s0.p0
|
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
|
levobupivacaine
|
phenobarbital
|
MECHANISM
|
Levobupivacaine_ddi.xml
|
DDI-DrugBank.d320.s3
|
DDI-DrugBank.d320.s3.p1
|
Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
|
Antithyroid agents
|
sodium iodide I131
|
EFFECT
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s3
|
DDI-DrugBank.d213.s3.p0
|
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
|
Fenfluramine
|
guanethidine
|
EFFECT
|
Fenfluramine_ddi.xml
|
DDI-DrugBank.d104.s0
|
DDI-DrugBank.d104.s0.p1
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
cannabinoids
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p55
|
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
|
Diphenhydramine hydrochloride
|
hypnotics
|
EFFECT
|
Diphenhydramine_ddi.xml
|
DDI-DrugBank.d296.s0
|
DDI-DrugBank.d296.s0.p2
|
Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
|
ethoxzolamide
|
amphotericin B
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s2
|
DDI-DrugBank.d286.s2.p1
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
benzodiazepines
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p8
|
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
|
adenosine
|
caffeine
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s4
|
DDI-DrugBank.d226.s4.p1
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
aluminum
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p11
|
astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
|
midazolam
|
cisapride
|
NONE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s11
|
DDI-DrugBank.d531.s11.p5
|
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
|
Digoxin
|
Nimodipine
|
NONE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s32
|
DDI-DrugBank.d289.s32.p0
|
FLEXERIL may have life-threatening interactions with MAO inhibitors.
|
FLEXERIL
|
MAO inhibitors
|
INT
|
Cyclobenzaprine_ddi.xml
|
DDI-DrugBank.d150.s0
|
DDI-DrugBank.d150.s0.p0
|
While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
|
fibrates
|
gemfibrozil
|
NONE
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s8
|
DDI-DrugBank.d12.s8.p0
|
Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
|
alosetron
|
hydralazine
|
EFFECT
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s15
|
DDI-DrugBank.d364.s15.p2
|
However, co administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
|
fexofenadine hydrochloride
|
erythromycin
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s1
|
DDI-DrugBank.d466.s1.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cinchophen
|
diazoxide
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p585
|
The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
|
ENABLEX
|
ketoconazole
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s0
|
DDI-DrugBank.d459.s0.p0
|
ERGAMISOL (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
|
levamisole hydrochloride
|
alcohol
|
EFFECT
|
Levamisole_ddi.xml
|
DDI-DrugBank.d381.s0
|
DDI-DrugBank.d381.s0.p2
|
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
|
clarithromycin
|
verapamil
|
NONE
|
Chlorpheniramine_ddi.xml
|
DDI-DrugBank.d235.s4
|
DDI-DrugBank.d235.s4.p35
|
However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
|
antiretroviral drugs
|
antineoplastic drugs
|
ADVISE
|
11148572.xml
|
DDI-MedLine.d115.s14
|
DDI-MedLine.d115.s14.p0
|
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
|
Codeine
|
anesthetics
|
EFFECT
|
Codeine_ddi.xml
|
DDI-DrugBank.d464.s0
|
DDI-DrugBank.d464.s0.p1
|
On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
|
gemfibrozil
|
bexarotene
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s2
|
DDI-DrugBank.d467.s2.p14
|
The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
|
trichlorfon
|
coumaphos
|
EFFECT
|
46730.xml
|
DDI-MedLine.d5.s3
|
DDI-MedLine.d5.s3.p0
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
perphenazine
|
phenylbutazone
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p143
|
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
|
FACTIVE
|
cimetidine
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s1
|
DDI-DrugBank.d347.s1.p1
|
Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
|
quinolones
|
zinc
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s7
|
DDI-DrugBank.d562.s7.p2
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
alprazolam
|
anticonvulsants
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p6
|
Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
|
Bromocriptine mesylate
|
butyrophenones
|
INT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s1
|
DDI-DrugBank.d272.s1.p1
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
CNS depressants
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p34
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
thiazides
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p4
|
Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
|
beta blockers
|
cardiac glycosides
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s35
|
DDI-DrugBank.d558.s35.p24
|
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
|
vasopressor drugs
|
ergot-type oxytocic drugs
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s3
|
DDI-DrugBank.d110.s3.p0
|
Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
|
antiepileptic drugs
|
phenytoin
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s18
|
DDI-DrugBank.d3.s18.p7
|
Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
|
alcohol
|
SINEQUAN
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s26
|
DDI-DrugBank.d223.s26.p2
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
phenobarbital
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p20
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
antifungals
|
temazepam
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p521
|
Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
|
ampicillin
|
allopurinol
|
EFFECT
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s16
|
DDI-DrugBank.d413.s16.p8
|
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
|
ciprofloxacin
|
Proquin XR
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s12
|
DDI-DrugBank.d123.s12.p4
|
Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
|
antacids
|
VIDEX
|
EFFECT
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s4
|
DDI-DrugBank.d43.s4.p7
|
astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
|
astemizole
|
triazolam
|
NONE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s11
|
DDI-DrugBank.d531.s11.p1
|
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
|
retinyl acetate
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s4
|
DDI-MedLine.d12.s4.p2
|
Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.
|
Digoxin
|
digoxin
|
NONE
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s21
|
DDI-DrugBank.d567.s21.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
amitriptyline
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p2
|
Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
|
Isoflurane
|
NUROMAX
|
MECHANISM
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s3
|
DDI-DrugBank.d267.s3.p2
|
Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45 (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
|
erythromycin
|
ergot alkaloid class
|
NONE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s5
|
DDI-DrugBank.d410.s5.p8
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
tramadol
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p39
|
Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
|
vitamin D
|
antiestrogens
|
NONE
|
7654327.xml
|
DDI-MedLine.d53.s0
|
DDI-MedLine.d53.s0.p0
|
Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
|
Diclofenac
|
lithium
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s8
|
DDI-DrugBank.d249.s8.p4
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
antibiotics
|
rifadin
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p164
|
Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
|
duloxetine
|
fluvoxamine
|
MECHANISM
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s1
|
DDI-DrugBank.d548.s1.p0
|
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
|
alprazolam
|
sertraline
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s9
|
DDI-DrugBank.d131.s9.p3
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
alprazolam
|
nicardipine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p9
|
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
|
chloroquine
|
digitoxin
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s16
|
DDI-DrugBank.d249.s16.p16
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
lamotrigine
|
ziprasidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p780
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
quinupristin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p21
|
Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
|
benzodiazepines
|
SUBUTEX
|
ADVISE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s7
|
DDI-DrugBank.d380.s7.p1
|
Effects of Other Antiepileptic Drugs on Felbatol Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
Phenytoin
|
Felbatol
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s30
|
DDI-DrugBank.d434.s30.p21
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
sulindac
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p47
|
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.
|
oxcarbazepine
|
contraceptives
|
NONE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s9
|
DDI-DrugBank.d307.s9.p2
|
Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
|
diuretics
|
hydralazine
|
NONE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s11
|
DDI-DrugBank.d561.s11.p13
|
Interaction of gentamycin and atracurium in anaesthetised horses.
|
gentamycin
|
atracurium
|
INT
|
8542840.xml
|
DDI-MedLine.d90.s0
|
DDI-MedLine.d90.s0.p0
|
Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
|
COPEGUS
|
didanosine
|
ADVISE
|
Peginterferon alfa-2a_ddi.xml
|
DDI-DrugBank.d196.s4
|
DDI-DrugBank.d196.s4.p2
|
While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
|
bupropion
|
carbamazepine
|
MECHANISM
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s8
|
DDI-DrugBank.d5.s8.p0
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
nortriptyline
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p3
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
platelet aggregation inhibitors
|
ardeparin
|
EFFECT
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p8
|
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
|
selective serotonin reuptake inhibitors
|
dihydroergotamine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s4
|
DDI-DrugBank.d423.s4.p3
|
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
|
beta-adrenergic receptor blocking agents
|
Anesthetics
|
INT
|
Nadolol_ddi.xml
|
DDI-DrugBank.d204.s0
|
DDI-DrugBank.d204.s0.p0
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
tamoxifen
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p11
|
Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
|
cholestyramine
|
hydrochlorothiazide
|
MECHANISM
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s5
|
DDI-DrugBank.d162.s5.p2
|
In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.
|
BROVANA
|
BROVANA
|
NONE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s10
|
DDI-DrugBank.d284.s10.p0
|
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
|
SSRIs
|
sumatriptan succinate
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s4
|
DDI-DrugBank.d423.s4.p5
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.